Mithra completes enrollment in Phase II trial of Donesta for vasomotor menopausal symptoms

Mithra Pharmaceuticals S.A. (Euronext:MITRA) completed enrollment of 260 patients with vasomotor menopausal symptoms in the double-blind, placebo-controlled, European Phase II E4 Relief trial to evaluate once-daily 2.5, 5, 10 and 15 mg oral Donesta for 12 weeks. The primary endpoint is daily minimum dose required to treat symptoms; secondary endpoints include vulvovaginal atrophy, lipid and glucose metabolism and bone metabolism markers...